The Developmental Research Program is an integral part of the UCSF Brain Tumor SPORE and represents the best opportunity to explore new ideas as pilot projects, to develop new resources and apply new technologies to translational research, and to promote collaborations among scientists at UCSF and outside institutions. The Developmental Research Program of the UCSF Brain Tumor SPORE has worked extremely well over the initial 5 years of SPORE funding, and has allowed us to meet all the stated goals of the program. A number of new technologies have come directly from work funded by the program including new whole-genome approaches to find aberrantly methylated genes and novel fusion transcripts in gliomas (Developmental Projects 3 and 4). Projects funded by the Developmental Research Program have also led to new and productive collaborations between UCSF investigators and industry, between UCSF Brain Tumor SPORE program and other UCSF SPORE programs, and between UCSF Brain Tumor SPORE investigators and investigators at other institutions. Most concretely, work funded by the Developmental Research Program (Developmental Project 1) has been incorporated into an expanded Project 4 of the new application, while that funded in Developmental Projects 2 and 5 has evolved and merged into a new full project (Project 5 in the current proposal). Because the mechanism used in the Developmental Research Program to encourage, select, monitor, and promote projects has clearly been successful, we will continue to use, and if necessary evolve the process in the proposed funding period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA097257-10S1
Application #
8540604
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
2011-05-01
Budget End
2013-04-30
Support Year
10
Fiscal Year
2012
Total Cost
$59,988
Indirect Cost
$21,440
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Hayes, Josie; Yu, Yao; Jalbert, Llewellyn E et al. (2017) Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas. Neuro Oncol :
Campbell, Brittany B; Light, Nicholas; Fabrizio, David et al. (2017) Comprehensive Analysis of Hypermutation in Human Cancer. Cell 171:1042-1056.e10
Neill, Evan; Luks, Tracy; Dayal, Manisha et al. (2017) Quantitative multi-modal MR imaging as a non-invasive prognostic tool for patients with recurrent low-grade glioma. J Neurooncol 132:171-179
Wiencke, John K; Koestler, Devin C; Salas, Lucas A et al. (2017) Immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (NLR) in glioma survival. Clin Epigenetics 9:10
Raleigh, David R; Solomon, David A; Lloyd, Shane A et al. (2017) Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome. Neuro Oncol 19:78-88
Müller, Sören; Diaz, Aaron (2017) Single-Cell mRNA Sequencing in Cancer Research: Integrating the Genomic Fingerprint. Front Genet 8:73
López, Giselle; Oberheim Bush, Nancy Ann; Berger, Mitchel S et al. (2017) Diffuse non-midline glioma with H3F3A K27M mutation: a prognostic and treatment dilemma. Acta Neuropathol Commun 5:38
Lee, Julieann; Solomon, David A; Tihan, Tarik (2017) The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children. J Neurooncol 132:1-11
Jahangiri, Arman; Nguyen, Alan; Chandra, Ankush et al. (2017) Cross-activating c-Met/?1 integrin complex drives metastasis and invasive resistance in cancer. Proc Natl Acad Sci U S A 114:E8685-E8694
Kline, Cassie N; Joseph, Nancy M; Grenert, James P et al. (2017) Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. Neuro Oncol 19:699-709

Showing the most recent 10 out of 336 publications